You are now leaving

Please click 'Continue to external site' if you want to continue.

Late Phase Development

We currently have an active pipeline of new cancer care products in various stages of development, including compounds in Phase III clinical development.


Anamorelin is a novel, orally available, selective ghrelin receptor agonist that mimics the appetite-enhancing and anabolic effects of the ghrelin hormone.

Development status:

  • Approved in Japan
  • Phase III clinical studies (SCALA) ongoing globally